Almagate
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Oral | |
| Identifiers | |
| 66827-12-1 | |
| A02AD03 | |
| PubChem | CID 71749 |
| ChemSpider |
64792  |
| UNII |
568Z59H7ZJ |
| KEGG |
D02821 |
| Chemical data | |
| Formula | Al2Mg6(OH)14(CO3)2 · 4 H2O |
| 314.99 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Almagate (trade name Almax) is an aluminium- and magnesium-containing antacid. It was first described in 1984.[1][2]
Adverse effects
Almagate is well tolerated. In a clinical trial, the most common adverse effects were diarrhea and nausea.[3]
References
- ↑ Moragues, J. B. (1984). "Characterization of a new crystalline synthetic gastric antacid, almagate" (FREE FULL TEXT). Arzneimittel-Forschung 34 (10A): 1346–1349. ISSN 0004-4172. PMID 6548918.
- ↑ Beneyto, J. F. B. (1984). "Evaluation of a new antacid, almagate" (FREE FULL TEXT). Arzneimittel-Forschung 34 (10A): 1350–1354. ISSN 0004-4172. PMID 6439224.
- ↑ Suau, A. D.; Dominguez Martin, A; Ferrando Cucarella, J; Juncosa Iglesias, L; Muñoz Benitez, J; Nieto Calvet, M; Pérez Gieb, J; Pérez Mota, A; Pineda Garcia, A; Rodriguez Sanchez, E (1984). "Treatment of gastric pyrosis with almagate in patients with and without endoscopically demonstrable duodenal ulcer. A multicentre clinical trial" (FREE FULL TEXT). Arzneimittel-Forschung 34 (10A): 1380–1383. ISSN 0004-4172. PMID 6548926.
| ||||||||||||||||||||||||||||||||||||||||